Aims: We aimed to compare patients' quality of life (QoL) after two types of atrial fibrillation (AF) treatment: a hybrid ablation strategy and a surgical CryoMaze procedure alone. Methods and results: Patients with non-paroxysmal AF undergoing coronary artery bypass grafting and/or valve repair/replacement with concomitant CryoMaze procedure were randomly assigned to undergo either radiofrequency catheter ablation after three months (Hybrid Group) or no further treatment (Surgery Group). QoL was compared using the Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire. The AFEQT score was converted to the scale of 0 to 100 per cent points, i.e., a score of 0 corresponds to complete disability (or responding "extremely" limited, difficult, or bothersome to all questions answered), and a score of 100 corresponds to no disability (or responding "not at all" limited, difficult, or bothersome to all questions answered). In 106 Hybrid Group patients and 109 Surgery Group patients, both baseline and 12-month AFEQT data were available for final analysis. Patients' QoL did not differ between the Hybrid and Surgery Groups at baseline. At 12 months post-procedure, QoL improved significantly in both groups (from 61.9 ± 16.3 to 86.5 ± 13.4 and from 58.6 ± 14.9 to 81.5 ± 16.7 in the Hybrid Group and Surgery Group, respectively, P < 0.001). The 12-month AFEQT score was significantly higher in the Hybrid Group compared to the Surgery Group (P = 0.017). In an analysis based on AF recurrence, the QoL at 12 months was significantly higher in patients without AF recurrences compared to patients with AF recurrences (86.2 ± 14.0 vs 80.2 ± 16.8, P = 0.005). Conclusion: Compared to the CryoMaze procedure alone, the hybrid ablation strategy was associated with higher QoL 12 months post-procedure in patients with non-paroxysmal AF undergoing cardiac surgery for structural heart disease. Arrhythmia recurrence was the most significant denominator of the QoL after concomitant AF surgery.
- Klíčová slova
- CryoMaze,
- MeSH
- fibrilace síní * chirurgie MeSH
- kardiochirurgické výkony metody MeSH
- katetrizační ablace metody škodlivé účinky MeSH
- koronární bypass metody MeSH
- kvalita života MeSH
- lidé středního věku MeSH
- lidé MeSH
- maze procedura * metody MeSH
- průzkumy a dotazníky MeSH
- senioři MeSH
- statistika jako téma MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- práce podpořená grantem MeSH
- srovnávací studie MeSH
- Publikační typ
- abstrakt z konference MeSH
- Publikační typ
- abstrakt z konference MeSH
Telmisartan is an angiotensin receptor blocker (ARB) and a selective peroxisome proliferator activated receptor gamma (PPARG) modulator. Recently, we tested metabolic effects of telmisartan (5 mg/kg body weight) in spontaneously hypertensive rats (SHR) fed a diet containing 60 % fructose, a widely used model of the metabolic syndrome. Surprisingly, we observed acute toxic effects of telmisartan. Rats lost body weight rapidly and died within 2 to 3 weeks due to bleeding into the upper gastrointestinal tract. SHR fed a high fructose diet and treated with telmisartan exhibited rapid decrease in blood pressure when compared to the SHR fed a high fructose diet and treated with valsartan. Concentrations of both unconjugated telmisartan and telmisartan glucuronide in the liver of SHR rats fed a high fructose diet were approximately 4 fold higher when compared to Brown Norway (BN) rats fed the same diet. Plasma concentrations of unconjugated telmisartan in the SHR were about 5 fold higher when compared to BN rats while plasma levels of telmisartan glucuronide were similar between the strains. Testing of other rat strains, diets, and the ARB valsartan showed that toxic effects of telmisartan in combination with high fructose diet are specific for the SHR. These results are consistent with the possibility that in some circumstances, SHR are predisposed to telmisartan toxicity possibly because of a genetically determined disturbance in telmisartan metabolism.
- MeSH
- antihypertenziva toxicita MeSH
- dietní cukry aplikace a dávkování toxicita MeSH
- fruktosa aplikace a dávkování toxicita MeSH
- gastrointestinální trakt účinky léků patologie MeSH
- hypertenze genetika patologie MeSH
- krysa rodu rattus MeSH
- potkani inbrední SHR MeSH
- potkani Wistar MeSH
- telmisartan toxicita MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
The prophylaxis against microbial airway infections of cystic fibrosis (CF) patients is an emerging application of chicken yolk antibody (IgY), however, no data on the effect of inhaled IgY have been published yet. Rats were daily (for 28 days) exposed to an aerosol of IgY, ovalbumin (OVA), Fab fragment of IgY, or PBS and their serum, bronchoalveolar lavage (BAL) and lung tissue were examined for inflammation signs. There were no marked changes in lung parenchyma, except for an elevated number of alveolar macrophages in the OVA-exposed group. While the administration of OVA or IgY aerosols slightly increased levels of cytokine TNF-α and GRO/KC in BAL fluid, a marked elevation of GM-CSF in serum was observed after the OVA inhalation. The administration of Fab induced expression of IL-1β > IL-18 in serum, in contrast no effect exerted by IgY. Our results suggest that the aerosolized IgY did not cause any deleterious effects in rat lungs.
- MeSH
- aplikace inhalační * MeSH
- bronchoalveolární laváž MeSH
- cystická fibróza * prevence a kontrola MeSH
- cytokiny MeSH
- imunoglobuliny * MeSH
- krysa rodu rattus MeSH
- modely u zvířat MeSH
- protilátky MeSH
- Pseudomonas * účinky léků MeSH
- vaječný žloutek MeSH
- zánět MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- zvířata MeSH
- Publikační typ
- práce podpořená grantem MeSH
- Klíčová slova
- epikardiální preadipocyty, renální preadipocyty, epikardiální adipocyty, renální adipocyty, subkutánní preadipocyty, subkutánní adipocyty,
- MeSH
- adiponektin * imunologie metabolismus MeSH
- ateroskleróza * diagnóza etiologie patofyziologie MeSH
- kardiovaskulární nemoci * diagnóza etiologie metabolismus patofyziologie MeSH
- lidé MeSH
- perikard * anatomie a histologie fyziologie patofyziologie MeSH
- proliferace buněk * MeSH
- svaly hladké cévní * cytologie MeSH
- tuková tkáň * MeSH
- tukové buňky * sekrece MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- práce podpořená grantem MeSH
- Publikační typ
- abstrakt z konference MeSH
